Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack aftermath: which treatment causes less internal bleeding?

NCT ID NCT03677466

Knowledge-focused Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examined bleeding inside the heart muscle (intramyocardial hemorrhage) in 60 patients who had a severe type of heart attack called STEMI. Researchers compared two treatment strategies: giving clot-busting drugs followed by a procedure to open the artery, versus going straight to the artery-opening procedure. They used MRI scans to measure bleeding and heart function. The goal was to understand which approach might lead to better recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fibrinolytic drugs (Tenecteplase, Alteplase, Streptokinase) and PCI procedure
What this could lead to
If successful, this could help doctors choose the best treatment strategy to reduce heart muscle bleeding after a heart attack, potentially improving recovery.
What could go wrong
This was a small, observational study with only 60 participants, so results may not apply to everyone. It did not test a new treatment, only compared existing ones.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Jan 2018

Finished

Mar 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years at time of randomization (18 years and older); * Acute myocardial infarction; * Reperfusion of the infarct-related coronary artery in terms within 12 h of symptom onset; * Written the informed consent to participate in research; Exclusion Criteria: * Inability to obtain informed consent; * Patients previously undergone endovascular / surgical revascularization of coronary artery; * Severe comorbidity; * History of myocardial infarction; * History of intracranial haemorrhage; * Pulmonary edema, cardiogenic shock; * Creatinine clearance \<30 mL/min or dialysis; * Unable to undergo or contra-indications for MRI; * Allergy for contrast agent; * Indication or use of oral anticoagulant therapy; * Major bleedind; * Atrio-ventricular block II and III degree; * Active gastroduodenal ulcer; * Aortic dissection; * Acute psychotic disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction Myocardial injury Myocardial necrosis STEMI

Contacts and locations

Locations

  • Cardiology Research Institute

    Tomsk, 634012, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.